FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee.
The Teratology Society believes that the current FDA Use-in-Pregnancy Ratings should be abandoned. The Society recommends that drug labeling should include narrative statements that summarize and interpret available data regarding hazards of developmental toxicity and provide estimates of potential teratogenic risk.
D005260:Female; D006801:Humans; D011247:Pregnancy; D018570:Risk Assessment; D013723:Teratogens / Q000145:classification*; D014481:United States; D014486:United States Food and Drug Administration
D013723:Teratogens